Shannon Brown III

Chief Commercial Officer (cco) at OncoBeta - epidermal radioisotope therapy

Shannon Brown III is the Chief Commercial Officer for OncoBeta, a company specializing in epidermal radioisotope therapy. With a background in sales and marketing in the healthcare industry, Shannon has held various positions in pharmaceutical companies such as Basilea Pharmaceutica Ltd, Teva Pharma, GlaxoSmithKline, and Pfizer. Shannon also has experience as a Health Clinic Manager in the US Army. Shannon holds a degree from the College of Chicago and has received medical training from the US Army Medical Institute.

Location

Garching, Germany

Links

Previous companies


Org chart


Teams


Offices


OncoBeta - epidermal radioisotope therapy

OncoBeta® GmbH located in Garching near Munich is a manufacturer and service provider of innovative medical solutions specialized in the development and commercialization of state-of-the-art therapies utilizing epidermal radioisotopes. We are very proud to be a pioneer and innovator in the epidermal radioisotope sector, presently offering a therapeutic application for physicians to treat non-melanoma skin cancer. Our current flag ship solution is the Rhenium-SCT® (Skin Cancer Therapy) a novel treatment option for basal cell carcinomas (BCCs) or squamous cell carcinomas (SCCs) based on the local irradiation of tumors with the beta-emitter Rhenium-188. Rhenium-188 is an optimal isotope for the treatment of superficial lesions such as non-melanoma skin cancers due to its practical penetration of 2-3mm in human tissue. Since the radioactive Rhenium does not come in direct contact with the patient, the Rhenium-SCT® is seen as a patient-personalised brachytherapy with minimal radiation exposition and adverse effects. The Rhenium-SCT is a CE certified method arising from over 10 years of experience and clinical studies (>700 patients, >1900 lesions). It provides non-melanoma skin cancer patients with a single-session, painless, highly-effective non- surgical treatment with excellent aesthetic results and complete remissions in up to 98,5% of all cases. We are also currently evaluating further exciting applications and treatment possibilities with rhenium-188.


Headquarters

Garching, Germany

Employees

11-50

Links